Literature DB >> 22693179

Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis.

Manish Pareek1, Marion Bond, Jennifer Shorey, Suranjith Seneviratne, Margaret Guy, Peter White, Ajit Lalvani, Onn Min Kon.   

Abstract

BACKGROUND: UK tuberculosis (TB) notifications are rising due to disease in the immigrant population. National screening guidelines have been revised but cost-effectiveness analyses are hampered by the lack of data on the comparative performance of tuberculin skin tests (TSTs) and interferon γ release assays (IGRAs) in immigrants.
METHODS: Three-way evaluation of TSTs and two IGRAs (QuantiFERON Gold in-tube (QFN-GIT) and T-SPOT.TB) in immigrants aged ≥16 years to quantify test positivity, concordance and factors associated with positivity. Yields were computed at different incidence thresholds and the relative cost-effectiveness of screening was estimated using different latent TB infection (LTBI) screening modalities at varying incidence thresholds with or without port-of-arrival chest x-ray (CXR).
RESULTS: 231 immigrants were included; median age 29 (IQR 24-37). TSTs were accepted by 80.9%, read in 93.5% and 30.3% were positive - QFN-GIT and T-SPOT.TB positive in 16.6% and 22.5% respectively. Positive TSTs, QFN-GIT and T-SPOT.TB were independently associated with increasing TB incidence in immigrants' countries of origin (p=0.007, 0.007, 0.037 respectively). Implementing current guidance (threshold 40/100 000 per year) would identify 98-100% of LTBIs (depending on test) but entail testing 97-99% of the cohort; screening at 150/100 000 per year would identify 49-71% of LTBIs but only entail screening half the cohort. The two most cost-effective screening strategies were no port-of-entry chest radiography and screen with single-step QFN-GIT at 250/100 000 per year (incremental cost-effectiveness ratio (ICER)) £21 565.3/case averted); and no port-of-entry CXR and screen with single-step QFN-GIT at 150/100 000 per year (averted additional 7.8 TB cases; ICER £31 867.1/case averted).
CONCLUSIONS: UK immigrant screening could cost-effectively and safely eliminate mandatory CXR on arrival by emphasising systematic screening for LTBI with single-step IGRA. Intermediate incidence thresholds balance the need to identify as many imported LTBIs as possible against limited service capacity.

Entities:  

Mesh:

Year:  2012        PMID: 22693179      PMCID: PMC5741173          DOI: 10.1136/thoraxjnl-2011-201542

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

1.  Rethinking TB screening: politics, practicalities and the press.

Authors:  J Moore-Gillon; Peter D O Davies; L Peter Ormerod
Journal:  Thorax       Date:  2010-07-07       Impact factor: 9.139

2.  Contribution of a IFN-gamma assay in contact tracing for tuberculosis in a low-incidence, high immigration area.

Authors:  Jean-Paul Janssens; Pascale Roux-Lombard; Thomas Perneger; Marie Metzger; Regis Vivien; Thierry Rochat
Journal:  Swiss Med Wkly       Date:  2008-10-04       Impact factor: 2.193

3.  Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.

Authors:  F Marra; C A Marra; M Sadatsafavi; O Morán-Mendoza; V Cook; R K Elwood; M Morshed; R C Brunham; J M Fitzgerald
Journal:  Int J Tuberc Lung Dis       Date:  2008-12       Impact factor: 2.373

4.  Comparison of interferon-gamma release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study.

Authors:  Alasdair R J Bamford; Angela M Crook; Julia E Clark; Zohreh Nademi; Garth Dixon; James Y Paton; Anna Riddell; Francis Drobniewski; Andrew Riordan; Suzanne T Anderson; Amanda Williams; Sam Walters; Beate Kampmann
Journal:  Arch Dis Child       Date:  2009-10-08       Impact factor: 3.791

5.  Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden.

Authors:  Junior Mutsvangwa; Kerry A Millington; Kathryn Chaka; Tafadzwa Mavhudzi; Yin-Bun Cheung; Peter R Mason; Anthony E Butterworth; Elizabeth L Corbett; Ajit Lalvani
Journal:  Thorax       Date:  2010-04       Impact factor: 9.139

6.  Interferon-gamma releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants.

Authors:  G Orlando; S Merli; L Cordier; F Mazza; G Casazza; A M Villa; L Codecasa; E Negri; A Cargnel; M Ferrarese; G Rizzardini
Journal:  Infection       Date:  2010-04-22       Impact factor: 3.553

7.  Prevalence of tuberculin skin test positivity in clinical population in New York City.

Authors:  Jiehui Li; Sonal S Munsiff; Tracy B Agerton
Journal:  J Immigr Minor Health       Date:  2008-11-05

8.  Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.

Authors:  Anil Pooran; Helen Booth; Robert F Miller; Geoff Scott; Motasim Badri; Jim F Huggett; Graham Rook; Alimuddin Zumla; Keertan Dheda
Journal:  BMC Pulm Med       Date:  2010-02-22       Impact factor: 3.317

9.  Tuberculosis screening of migrants to low-burden nations: insights from evaluation of UK practice.

Authors:  M Pareek; I Abubakar; P J White; G P Garnett; A Lalvani
Journal:  Eur Respir J       Date:  2010-11-11       Impact factor: 16.671

10.  Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis.

Authors:  Manish Pareek; John P Watson; L Peter Ormerod; Onn Min Kon; Gerrit Woltmann; Peter J White; Ibrahim Abubakar; Ajit Lalvani
Journal:  Lancet Infect Dis       Date:  2011-04-20       Impact factor: 25.071

View more
  26 in total

1.  'Pre-entry screening for tuberculosis' commentary: authors' response.

Authors:  Robert W Aldridge; Tom A Yates; Dominik Zenner; Peter J White; Ibrahim Abubakar; Andrew C Hayward
Journal:  Pathog Glob Health       Date:  2015-06       Impact factor: 2.894

2.  Optimizing the detection of recent tuberculosis infection in children in a high tuberculosis-HIV burden setting.

Authors:  Anna M Mandalakas; H Lester Kirchner; Gerhard Walzl; Robert P Gie; H Simon Schaaf; Mark F Cotton; Harleen M S Grewal; Anneke C Hesseling
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

Review 3.  Gamma Interferon Assays Used in the Diagnosis of Tuberculosis.

Authors:  Rebecca T Horvat
Journal:  Clin Vaccine Immunol       Date:  2015-05-27

Review 4.  Defining a migrant-inclusive tuberculosis research agenda to end TB.

Authors:  P B Shete; D Boccia; P Dhavan; N Gebreselassie; K Lönnroth; S Marks; A Matteelli; D L Posey; M J van der Werf; C A Winston; C Lienhardt
Journal:  Int J Tuberc Lung Dis       Date:  2018-08-01       Impact factor: 2.373

5.  Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.

Authors:  Aran Singanayagam; Kavina Manalan; Saranya Sridhar; Philip L Molyneaux; David W Connell; Peter M George; Anne Kindelerer; Suranjith Seneviratne; Ajit Lalvani; Melissa Wickremasinghe; Onn Min Kon
Journal:  Thorax       Date:  2013-08-23       Impact factor: 9.139

Review 6.  A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries.

Authors:  Lorenzo Zammarchi; Gianluigi Casadei; Marianne Strohmeyer; Filippo Bartalesi; Carola Liendo; Alberto Matteelli; Maurizio Bonati; Eduardo Gotuzzo; Alessandro Bartoloni
Journal:  BMC Health Serv Res       Date:  2015-09-24       Impact factor: 2.655

7.  How should I interpret an interferon gamma release assay result for tuberculosis infection?

Authors:  Ibrahim Abubakar; Helen Ruth Stagg; Hilary Whitworth; Ajit Lalvani
Journal:  Thorax       Date:  2013-03       Impact factor: 9.139

8.  Cross-sectional study of prevalence and risk factors, and a cost-effectiveness evaluation of screening and preventive treatment strategies for latent tuberculosis among migrants in Singapore.

Authors:  Vanessa W Lim; Hwee Lin Wee; Phoebe Lee; Yijun Lin; Yi Roe Tan; Mei Xuan Tan; Lydia Wenxin Lin; Peiling Yap; Cynthia Be Chee; Timothy Barkham; Vernon Lee; Mark Chen; Rick Twee-Hee Ong
Journal:  BMJ Open       Date:  2021-07-15       Impact factor: 2.692

9.  Treating latent TB in primary care: a survey of enablers and barriers among UK General Practitioners.

Authors:  Christina Atchison; Dominik Zenner; Lily Barnett; Manish Pareek
Journal:  BMC Infect Dis       Date:  2015-08-13       Impact factor: 3.090

10.  Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.

Authors:  Matthew K O'Shea; Thomas E Fletcher; Nicholas J Beeching; Martin Dedicoat; David Spence; Helen McShane; Adam F Cunningham; Duncan Wilson
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.